Improving the finding of African swine fever virus antibodies in serum
African pig fever (ASF) is an exceptionally irresistible and lethal illness of pigs. Because of the intricacy of the ASF infection (ASFV) and different clinical types of the illness, an extensive variety of exceptionally powerful and vigorous sero-demonstrative tests are required.
The use of the most antigenic ASFV proteins is highly crucial to improving sero-diagnostic assays. Currently, only a few highly antigenic recombinant proteins have been tested and validated for use as reagents in ASF sero-diagnostic assays. So far, three ELISA kits based on the recombinant proteins P72, P30, and PP62 have been approved. In a new study published in Biosafety and Health based on the recombinant P22 protein, a highly sensitive, specific, and rapid P22 monoclonal antibody-based blocking ELISA (mAb-bELISA) assay was developed to detect serum antibodies induced by genotype I and II ASFVs to detect ASFV antibodies. A total of 806 pig serum samples were tested to evaluate the performance of the diagnostic assay. The assay was able to detect ASFV antibodies as early as 9 days post-infection.
In light of this review, the noval P22-mAb based bELISA examine can be utilized for fast and precise recognition of antibodies against ASFV, which will assume a significant part in the control and counteraction of ASF as an option in contrast to other serological demonstrative strategies. Additionally, this study will help analysts to additionally examine the immunogenic significance of the P22 protein in ASFV contamination.